Израел - иврит - Ministry of Health

teva medical marketing ltd. - glucose monohydrate - תמיסה לאינפוזיה - glucose monohydrate 5.5 %w/v - glucose - glucose - glucose 5 % intravenous infusion is indicated for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

Израел - иврит - Ministry of Health

teva medical marketing ltd. - glucose monohydrate - תמיסה לאינפוזיה - glucose monohydrate 5.5 %w/v - glucose - glucose - glucose 5 % intravenous infusion is indicated for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

Израел - иврит - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 % - sodium chloride - sodium chloride - a source of water and electrolytes. also indicated for use as priming solutions in hemodialysis procedures.

Израел - иврит - Ministry of Health

teva medical marketing ltd. - calcium chloride dihydrate; potassium chloride; sodium chloride; sodium lactate - תמיסה לאינפוזיה - sodium lactate 0.32 %w/v; calcium chloride dihydrate 0.027 %w/v; potassium chloride 0.04 %w/v; sodium chloride 0.6 %w/v - calcium chloride - calcium chloride - source of water and electrolytes. regulation or maintenance of metabolic acidosis ( except lactic acidosis).

Израел - иврит - Ministry of Health

remedix care ltd - glycine; l- alanine; l- aspartic acid; l- cysteine; l- glutamic acid; l- isoleucine; l- leucine; l- lysine; l- methionine; l- ornithine hydrochloride; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; taurine - תמיסה לאינפוזיה - l- valine 0.76 g / 100 ml; l- tyrosine 0.045 g / 100 ml; l- tryptophan 0.2 g / 100 ml; l- threonine 0.37 g / 100 ml; taurine 0.06 g / 100 ml; l- serine 0.4 g / 100 ml; l- proline 0.3 g / 100 ml; l- phenylalanine 0.42 g / 100 ml; l- ornithine hydrochloride 0.318 g / 100 ml; l- methionine 0.24 g / 100 ml; l- lysine 1.1 g / 100 ml; l- leucine 1.0 g / 100 ml; l- isoleucine 0.67 g / 100 ml; l-histidine 0.38 g / 100 ml; glycine 0.4 g / 100 ml; l- glutamic acid 1.0 g / 100 ml; l- cysteine 0.189 g / 100 ml; l- aspartic acid 0.6 g / 100 ml; l-arginine 0.84 g / 100 ml; l- alanine 0.8 g / 100 ml - lysine - lysine - primene 10 % is indicated in 1) children and infants 2) neonates at term or premature of normal or low birth weight when oral or enteral nutrition is impossible insufficient or contraindicated.

Израел - иврит - Ministry of Health

teva medical marketing ltd. - gentamicin as sulfate 80 mg / 100 ml - solution for injection - gentamicin - treatment of serious infections caused by susceptible microorganisms.

Израел - иврит - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

Израел - иврит - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

Израел - иврит - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

Израел - иврит - Ministry of Health

takeda israel ltd - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 100 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - ivig can be used in all age ranges, unless otherwise specified below.replacement therapy in:primary immunodeficiency syndromes with impaired antibody production.hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed.hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation.children and adolescents (age 0-18) with congenital aids and recurrent bacterial infections.hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (hsct).immunomodulationprimary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count.guillain barr? syndrome.kawasaki disease.